TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06058416

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Healive (hepatitis A vacine(human diploid cell), inactivated)
Description: The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Healive (hepatitis A vacine(human diploid cell), inactivated)
Description: The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Healive (hepatitis A vacine(human diploid cell), inactivated)
Description: The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Healive (hepatitis A vacine(human diploid cell), inactivated)
Description: The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively.
Study: NCT05782348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Description: A six-session CBI Intervention component will be used with the TEST GROUP I. This will examine a cognitive behavioral intervention designed to improve tooth brushing and oral hygiene. The components include oral health education, values-based activities, motivational interviewing, goal setting, problem solving skills, cognitive restructuring, verbal reinforcement and stress management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate smart toothbrush
Description: A Colgate smart toothbrush that provides the user with details on toothbrushing habits and frequency

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate smart toothbrush
Description: A Colgate smart toothbrush that provides the user with details on toothbrushing habits and frequency
Study: NCT06597019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg and inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
Study: NCT06249919

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NS101
Description: NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NS101
Description: NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
Study: NCT05904275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caudal epidural injection
Description: Preoperative Ultrasound guided caudal epidural injection in lumbosacral spine surgeries for postoperative analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caudal epidural injection
Description: Preoperative Ultrasound guided caudal epidural injection in lumbosacral spine surgeries for postoperative analgesia.
Study: NCT06096714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine will be infused using a pump.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine
Description: Nicotine will be infused using a pump.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline with be used to compare Nicotine, Saline will be infused using a pump

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline with be used to compare Nicotine, Saline will be infused using a pump
Study: NCT04904016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowOx™
Description: The FlowOx™ system generates a negative oscillating pressure which cause rapid fluctuations in blood flow in the leg and foot.
Study: NCT04970810

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Diabetes Goal
Description: Subjects enrolled in the MDG arm will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Diabetes Goal + CommunityRx
Description: Subjects enrolled in the MDG arm + CRx will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls. Participants will also receive a HealtheRx (personalized resource prescriptions) for community organizations.
Study: NCT06504368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PDL1
Description: Solution for IV Infusion
Study: NCT06554886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: Cryoneurolysis
Study: NCT06181318

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiparametric MRI scan of the liver
Description: MRI scans will be performed at the Champalimaud Foundation using a 1.5T scanner after patients have fasted for 4 hours. Transverse abdominal T1 maps will be acquired to estimate extracellular fluid (which increases in cases of fibrosis and inflammation) and T2\* maps will be acquired to estimate liver iron levels. These quantitative MRI maps will be laid onto the volumetric images of Couinaud segments. Multi-slice quantitative maps will be generated using Liver MultiScan software (Perspectum, UK) with operators blinded to patient status. T1 measurements will be adjusted for the iron level to give iron-corrected T1 maps (cT1). Reference ranges for cT1 have been defined in the general population. PDFF maps of the liver will be calculated using MRI multi-echo and spoiled-gradient-echo acquisition. No intravenous contrast agents will be used in Liver MultiScan maps and the total scan duration will be approximately 30 minutes.
Study: NCT05416450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravaginal electrical stimulation added to bladder training
Description: BT was given as a home program. After information session, squeezing the PFM was shown in practice at least once to use in the urgency suppression strategies via digital palpation technique. The second stage strategies was aimed to delay urination, inhibit detrusor contraction, and prevent urgency by squeezing the PFM several times on a row, breathing deeply and self-motivating. In the third stage, a timed voiding program was started; a timed voiding and increasing the time between urination considering the voiding diary. IVES was applied in addition to BT in both groups. It was performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with a vaginal probe; three days a week, a total of 24 sessions for 8 weeks. Every session lasted 20 minutes. The stimulation parameters were a 10 Hz of frequency, a 5-10 s of work-rest cycle duration and, a 100 ms of pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100 mA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravaginal electrical stimulation added to bladder training
Description: BT was given as a home program. After information session, squeezing the PFM was shown in practice at least once to use in the urgency suppression strategies via digital palpation technique. The second stage strategies was aimed to delay urination, inhibit detrusor contraction, and prevent urgency by squeezing the PFM several times on a row, breathing deeply and self-motivating. In the third stage, a timed voiding program was started; a timed voiding and increasing the time between urination considering the voiding diary. IVES was applied in addition to BT in both groups. It was performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with a vaginal probe; three days a week, a total of 24 sessions for 8 weeks. Every session lasted 20 minutes. The stimulation parameters were a 10 Hz of frequency, a 5-10 s of work-rest cycle duration and, a 100 ms of pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100 mA.
Study: NCT06247085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegtibatinase
Description: Full Target Dose of pegtibatinase BIW

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: volume-matched saline SC BIW
Study: NCT05228691

Intervention type: OTHER
Intervention: Evaluation and Education
Description: A functional physical evaluation will be carried out and they will be informed about the characteristics of their symptoms. After the evaluation, they will be taught a guideline of exercises and recommendations.
Study: NCT06188754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Limiting food intake to 10 hours per day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Dietary advice designed to improve consumption of vegetables, fruits, whole grains, and the use of olive oil.
Study: NCT05222087

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 35Gy/5# Central 40Gy/5# Large Tumours \>5cm (non-central) 36Gy/12# or 40Gy/15# Ultracentral lesions 50Gy/5# Peripheral Tumours ≤5cm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoC systemic therapy
Description: Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoC systemic therapy
Description: Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.
Study: NCT05038228

Intervention type: DRUG
Intervention: Apixaban
Description: Anticoagulant

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Anticoagulant

Intervention type: DRUG
Intervention: Dabigatran
Description: Anticoagulant

Intervention type: DRUG
Intervention: Vitamin K antagonist (VKA)
Description: Anticoagulant
Study: NCT04833855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab Dose 1
Description: Subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab Dose 1
Description: Subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab Dose 2
Description: Subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab Dose 2
Description: Subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection.
Study: NCT04776954

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced Air Warming System
Description: The forced air warming system has a heater unit that blows air through a conduit to an air blanket that inflates with forced air that circulates throughout the blanket, and exits through tiny perforations on the patient-side of that blanket. The heat primarily warms the subject through convective means. As the warmed air escapes through the perforations in the blanket, it creates an environment of continuously circulating warm air that is in contact with the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resistive Blanket Warming System
Description: This blanket is equivalent to an operating-room-safe electric blanket. Through a power cord, a separate power source powers a semiconductor layer within the resistive blanket to generate heat. The heat primarily warms the subject by conductive warming through direct skin contact, and, secondarily, by warming the air around the participant in areas where there is no direct skin contact.
Study: NCT05724446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Clobetasol propionate ophthalmic nanoemulsion 0.05 % is an oil-in-water (O/W), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate ophthalmic suspension, 1%
Description: Microfine sterile ophthalmic suspension of dense and whitish appearance.
Study: NCT04924374

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiota Transplant plus anti PD1 therapy
Description: Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (\>30g/day).~anti PD1 therapy every 2-3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti PD1 therapy
Description: anti PD1 therapy every 2-3 weeks
Study: NCT05762484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser hair removal
Description: Using the Nd:YAG laser (cynergy), hair of the axillae will be removed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1 % Topical Lotion
Description: Clindamycin 1% lotion if needed
Study: NCT06008093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles. Durvalumab will also be given during the maintenance phase q4w until disease progression or unacceptable toxicity and at week 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Participants will receive IV Tremelimumab q3w for four 21-day cycles. Tremelimumab will also be given during the maintenance therapy phase at week 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive IV pemetrexed q3w for four 21-day cycles and q4w until disease progression or unacceptable toxicity. During the maintenance therapy phase, participants may receive an additional cycle of pemetrexed, where applicable, at Week 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive IV pembrolizumab q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive IV Carboplatin on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive IV Carboplatin on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive IV pemetrexed q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.
Study: NCT05540873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYB-103
Description: Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
Study: NCT04878991

Intervention type: DIAGNOSTIC_TEST
Intervention: Overture Metabolomics Embryo Selection
Description: Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
Study: NCT06386627

Intervention type: DIAGNOSTIC_TEST
Intervention: Stimulus response task
Description: Participants were tasked with performing a finger extension exercise that required pressing buttons in response to visual stimuli. In cases where physical movement was not possible, participants were instructed to imagine performing the task while focusing on their fingers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stimulus response task
Description: Participants were tasked with performing a finger extension exercise that required pressing buttons in response to visual stimuli. In cases where physical movement was not possible, participants were instructed to imagine performing the task while focusing on their fingers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation to assess the integrity of corticospinal connections
Study: NCT05966779

Intervention type: OTHER
Intervention: modified CDT physical therapy protocol, based on Godoy's Method
Description: modified CDT physical therapy protocol
Study: NCT05800405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Receive CAR-T per standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Receive leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05756010

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EMG
Description: The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG
Description: The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises
Study: NCT06176716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-26
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-26
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-26
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
Study: NCT05956626

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410ST
Description: Subretinal Administration of OCU410ST

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410ST
Description: Subretinal Administration of OCU410ST

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410ST
Description: Subretinal Administration of OCU410ST

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410ST
Description: Subretinal Administration of OCU410ST

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410ST
Description: Subretinal Administration of OCU410ST

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410ST
Description: Subretinal Administration of OCU410ST

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410ST
Description: Subretinal Administration of OCU410ST
Study: NCT06108869

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Control group
Description: Participants will still meet as a group for first two weeks, before beginning with the ABT practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Control group
Description: Participants will still meet as a group for first two weeks, before beginning with the ABT practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Control group
Description: Participants will still meet as a group for first two weeks, before beginning with the ABT practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Control group
Description: Participants will still meet as a group for first two weeks, before beginning with the ABT practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Control group
Description: Participants will still meet as a group for first two weeks, before beginning with the ABT practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Control group
Description: Participants will still meet as a group for first two weeks, before beginning with the ABT practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Control group
Description: Participants will still meet as a group for first two weeks, before beginning with the ABT practice.
Study: NCT04738825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management with stepped care to PrEP adherence and support services (CoMPASS)
Description: Participants will receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12 will be stepped up to receive PrEP adherence and support services (n=5).